Know Cancer

forgot password

Rituximab-HCVAD Alternating Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger

Phase 2
16 Years
60 Years
Open (Enrolling)

Thank you

Trial Information

Rituximab-HCVAD Alternating Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger

This study originally involved 2 different study drug regimens, R-CHOP and R-HCVAD. R-CHOP
is made up of rituximab, cyclophosphamide, vincristine, and prednisone, and is the most
common treatment for patients with non-Hodgkin's lymphoma. This combination was compared
with R-HCVAD, which is made up of rituximab, doxorubicin, cyclophosphamide, vincristine, and

Rituximab (Rituxan®) is a humanized monoclonal antibody against CD20 (a receptor in the
surface of malignant B-cell lymphocytes). The drug has activity against aggressive and
nonaggressive NHL of B-cell origin, and has been used in combination with chemotherapy.
Cyclophosphamide is a type of drug know as an alkylating agent. Vincristine is a type of
drug called vinca alkaloids. It is typically used in lymphomas, leukemias, and other
tumors. Prednisone is a type of steroid. Dexamethasone is a steroid that may have activity
against lymphomas. Methotrexate is an anti-cancer drug and a folic acid antagonist. It is
used to treat solid tumors, lymphomas, leukemias, and autoimmune diseases.

When this study began, participants were randomly assigned (as in the flip of a coin) to 1
of 2 arms: Arm A (R-HCVAD alternating with a combination of rituximab, methotrexate, and
Ara-C) or Arm B (R-CHOP). From this point on, all new participants will be treated with
the Arm A combination, which has shown to be better.

If you are found to be eligible to take part in this study, you will be given the study
drugs in 21-day cycles. The cycles will alternate between R-HCVAD and a combination of
rituximab, methotrexate, and Ara-C. During Cycle 1 (the R-HCVAD cycle), you will receive
rituximab through a needle in your vein (intravenously, or "IV"), on Day 1. The infusion
will take about 1 hour. Cyclophosphamide will be given by IV every 12 hours for 3 days.
Each infusion of cyclophosphamide will take about 3 hours. Doxorubicin will be given as a
15-minute infusion on Day 5 with the supervision of a nurse. Your doctor may also choose to
give you the doxorubicin over 24-48 hours using a small pump that you will carry around your
waist in a "fanny pack." You will not have to stay in the hospital to receive this study
drug. Vincristine will be given by IV, on Days 5 and 12. Each vincristine infusion will
take about an hour. Dexamethasone will be given by mouth (as a pill, capsule, or tablet) on
Days 2-5 and 12-15. You will also be given other standard medications to help prevent
possible side effects of these medications (such as nausea, vomiting, or rash).

In Cycle 2 (the rituximab-methotrexate-Ara-C cycle), you will receive rituximab on Day 1.
You will receive methotrexate by IV (after finishing the rituximab) on Days 2 and 3. The
infusion will take about 24 hours. You will be given a small "fanny pack" with a pump
inside that will slowly infuse the drug. You do not have to stay in the hospital while the
drug is being given. You will be given Ara-C every 12 hours on Days 3-4 (a total of 4
doses). You will be given other standard medications to help prevent possible side effects
of these medications (such as nausea, vomiting, or rash) during this cycle also.

Leucovorin is given 12 hours after each methotrexate infusion. It is used to stop the
action of the methotrexate and to prevent/lessen any side effects that the methotrexate may

During treatment, you will have blood draws (between 2-3 tablespoons) every week for routine
tests. Every 4 weeks during treatment , you will be asked questions about your medical
history and have a physical exam to check for any side effects. Every 2 cycles (about every
8 weeks), you will have bone marrow biopsies performed (if they were positive before
starting on this study), until they come back negative. You will have a PET scan to see if
the tumor is responding. Once the PET scan comes back negative, it will be up to your
physician to decide if you need additional PET scan tests, and when. You will have CT scans
of the chest, abdomen, pelvis, and neck every 2 cycles, if they were positive at the
beginning of the study also. You may have additional testing done while on this study, if
your physician feels that it is needed (for example, if it is needed to check for side

You may receive additional medication called "CNS prophylaxis" before receiving the study
treatments. Your doctor will discuss these medications with you. The "CNS prophylaxis"
consists of an alternating dose of either doxorubicin or methotrexate. The methotrexate
will be given either by IV pump or by a "lumbar puncture" (a needle inserted into the space
between the vertebrae in your back to infuse the drug directly into the spinal area). The
doxorubicin will be given by IV. Changes in the dose level of CNS prophylaxis will be
approved if you are at risk for or are experiencing serious side effects.

You will receive the study drugs for up to 6-8 cycles on an outpatient basis. This means
you will not have to be admitted to the hospital to receive the study drugs. You may be
taken off study if the disease gets worse. If you experience intolerable side effects while
taking any of the study drugs, your study doctor may decide to delay your treatment for up
to 3 weeks (one study cycle) or to continue your therapy on the drugs at a lower dose. If
the side effects become very severe, your doctor may decide to take you off of the study and
stop the medication.

At the end of your scheduled treatments, you will be asked to return to the clinic for
follow-up visits every 6 months for the first, second, third, and fourth year after
treatment on this study. You will then be followed every year after that. If your doctor
feels it is necessary, you may have blood tests (about 3-5 teaspoons) performed at these
visits. You will have bone marrow biopsies every other year for the first 2 years, if they
were positive before you started on this study, and then every year after that. At these
visits, you will be asked about any side effects you may have experienced and whether or not
your cancer has come back. If your doctor feels there is a chance that the cancer has come
back, he or she may schedule x-rays or scans in order to check. You will also be asked
about any other therapies you may be having to treat your cancer, if it has come back.

If you are taken off study for any reason, you will be asked to come back to the clinic for
an end-of-treatment visit within 4 weeks from the last treatment. This visit will include a
physical exam, routine blood tests (about 5-8 teaspoons), a blood-pregnancy test for women
who are able to get pregnant, an ECG, and a chest x-ray.

This is an investigational study. All of the study drugs are approved by the FDA for the
treatment of lymphoma. Up to 66 patients will take part in this study. All of the patients
will be enrolled at MD Anderson.

Inclusion Criteria:

1. Confirmed diagnosis of previously untreated large B-cell Non Hodgkin's, Large Cell
Lymphoma and B-Cell with high grade features. Other aggressive lymphomas such as
Primary Mediastinal large B-cell Lymphomas will be also allowed to be included.

2. Patients with performance status of 0-2 (Zubrod Scale).

3. Serum bilirubin <1.5 mg/dl and serum creatinine < 2.0 mg/dl unless due to lymphoma;
ANC >1000/mm^3 and platelets >100,000/mm^3 unless due to lymphoma.

4. Cardiac ejection fraction 50% or greater.

5. Ages 16 - 60 years (due to the fact that CHOP-R is not studied enough in younger
patients and is not considered standard of care).

6. Patients must be willing to receive transfusions of blood products.

7. Age adjusted International Prognostic Index Score of 2 or more

8. Previous steroids are allowed (if used to relieve some symptoms such as SVC, etc).

Exclusion Criteria:

1. Pregnancy (excluded due to the teratogenicity of the involved chemotherapy agents

2. Positive HIV serology because of poor tolerance to this intense chemotherapy regimen

3. Burkitt's lymphomas, and Mantle cell lymphoma, transformed follicular center cell
lymphoma, follicular grade III.

4. Any clinical or cytological diagnosis of CNS involvement

5. Any co-morbid medical, such as Child's Class C liver cirrhosis, end-stage renal
disease, and symptomatic congestive heart failure, or psychiatric illnesses that
preclude treatment with intense dose chemotherapy as determined by the primary

6. Concurrent or previous malignancy whose prognosis is poor (< 90% probability of
survival at 5 years)

7. Active Hepatitis B or C. Chronic carriers for Hepatitis B will be excluded.

Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Overall Response

Outcome Time Frame:

4 Months

Safety Issue:


Principal Investigator

Luis E. Fayad, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

UT MD Anderson Cancer Center


United States: Institutional Review Board

Study ID:




Start Date:

August 2005

Completion Date:

Related Keywords:

  • Lymphoma
  • Non-Hodgkin's Lymphoma
  • B-Cell Non-Hodgkin's Lymphoma
  • Lymphoma
  • Cyclophosphamide
  • Cytarabine
  • Doxorubicin
  • Hyper-CVAD
  • Methotrexate
  • Prednisone
  • Rituximab
  • Vincristine
  • R-CHOP
  • Dexamethasone
  • Decadron
  • Leucovorin
  • Ara-C
  • Cytosar
  • Cytoxan
  • DepoCyt
  • Cytosine arabinosine hydrochloride
  • AD
  • Hydroxydaunomycin hydrochloride
  • Neosar
  • Lymphoma
  • Lymphoma, Non-Hodgkin
  • Lymphoma, B-Cell



UT MD Anderson Cancer Center Houston, Texas  77030